Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, November 13, 2025
Meeting Time	12:04 PM –12:50 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Carlene Brandon, MS. (Local Non-affiliated Member) 6. Anastasia Zimmerman, Ph.D. (Local Non-affiliated Member) 7. Aimee McRae-Clar, Pharm.D., BCPP (IBC Alternate Member; Office of Research Integrity Director) 8. Logan Patterson, Ph.D. (IBC Member)
Quorum	Number of Members Present (Voting): 8 Number of Members Not Present: 3 Late Arrival of Voting Members: 0 Early Departure of Voting Members:0
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
Call to Order	The IBC Chair called the meeting to order at 12:04 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	July 10, 2025, August 14, 2025, September 11, 2025 and October 9, 2025, IBC meeting minutes were discussed and approved. Voting: (Total =8, For =8, Opposed =0, Abstain = 0).
Review of Prior Business	Discussed the on-going development an IBC Member Training Program to better equip IBC members with the knowledge, skills, and perspective as outlined in the NIH Guidelines and institutional policy.
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-333
PI Name	Delgado, Evan
Study Title	Liver growth and neoplasia
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes

	☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	molecular grade E. coli, adeno-associated viral vector,
Transgene expression	Mutant beta-catenin, MET tyosine kinase, Mutant NFE2L2, Myc, Sleeping Beauty transposon system, GFP, Cre recombinase, GLUL
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-337
PI Name	Engevik, Amy
Study Title	Engevik, Amy_MUSC Transgenic & Genome Editing Core [redacted] Mice
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D4b, III-E-3

Genetically modified microbes or vectors			
Transgene expression	[redacted]		
Highest BSL	BSL1, ABSL1		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☒ BSL1 ☐ BSL2 ☒ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-334
PI Name	Duncan, Stephen
Study Title	CDLD Cell Models Core and DDRCC Analytical Cell Models Core
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	
Transgene expression	Cas9
Highest BSL	BSL2
Training	☒ Complete ☐ Pending

Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-338
PI Name	Sambumurti, Kumar
Study Title	Protein processing and accumulation in neurodegeneration
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☒ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	E. coli, Leishmania, viral vectors (retrovirus, lentivirus, adeno-associated virus)
Transgene expression	Alzheimer amyloid protein (Abeta) precursor (APP), Alpha synuclein (SNCA), Microtubule-associated protein Tau (MAPT), Presenilin 1 (PSEN1) Presenilin 2 (PSEN2), Beta-site APP-cleaving enzyme (BACE1 and BACE2), Nicastrin (NCT), Gamma secretase complex (PSEN1/2, APH1a/b, PEN2, and NCT), apolipoprotein E (APOE), Notch, Vascular endothelial growth factor (VEGF), VEGF receptors, MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE C (MEF2C), Neprilysin (NEP), insulysin (IDE), Endothelin converting enzyme (ECE), Cathepsin D (CATD), Cathepsin S (CATS), Calpain, and their regulatory RNAs, cabbage looper moth genomic transposase.
Highest BSL	BSL2

Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-330
PI Name	Voelkel-Johnson, Christina
Study Title	Voelkel-Johnson IBC
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified rodent cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	E. coli, replication-deficient adenoviral or lentiviral vectors.
Transgene expression	ASAH1, CDKN1A/p21, GFP, RFP, luciferase
Highest BSL	BSL-2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☒ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒

	Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:7	Against:0	Abstained:0	Recused:1

Amendment

Protocol #	IBC-25-135
PI Name	Han, Lu
Study Title	Interactions between tumor cells and stromal cells
Agent	☒ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☒ Biological toxins ☒ Gene modified rodent cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	E. coli, retroviral and lentiviral vectors
Transgene expression	GATA6, FOXF1, FOXF2, CAS9
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review

First:	Voelkel-Johnson	Second:	Woodward
Votes			
For:8	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 12:50 PM